

12 June 2025

## FY2025 Full Year Revenue Guidance Upgrade

**Bioxyne Limited (ASX: BXN)** (Bioxyne or Company) upgrades full year FY2025 revenue guidance to \$28,000,000.

### Key Highlights:

- Full Year FY2025 Revenue guidance upgraded from \$25m to \$28m.
- Revenue for H1 FY2025 was \$12.6m, which represented a 267% increase on the previous half.
- Revenue for H2 FY2025 is expected to be \$15.4m, which represents a 226% increase on the prior corresponding period (H2 FY2024).
- Australian pharmaceutical manufacturing and supply has been a key driver of growth in FY25, and the Company expects continued growth in its Australian operations in FY2026.
- The Company is making significant progress in Germany and the UK and will provide a market update shortly.
- BLSMD40 and BLSMD100 (BLS manufactured MDMA capsules) going into commercial batch production in July.

Bioxyne's wholly owned subsidiary Breathe Life Sciences (BLS) is the Australian market leader in the manufacture of medicinal cannabis, MDMA, and Psilocybin products, contributing to Bioxyne's growth in FY2025.

Bioxyne operates in Medical Cannabis markets with estimated annualized revenues of >\$3bn in 2025; Australia and Germany each represent ~A\$1bn per year, and the UK and other EU markets a further ~\$1bn. According to Business Research, the global psychedelic drugs market is projected to grow to A\$14bn by 2032, with PTSD treatments representing ~\$3.5bn per year, and Treatment Resistant Depression ~\$5bn, reflecting increasing acceptance and demand for psychedelic-assisted therapies<sup>12</sup>. Bioxyne is positioning for long term success in its psychedelic business, and has progressed development of its MDMA capsules, BLSMD40 and BLSMD100, going into commercial batch production in July.

### Positive Outlook for FY2026

Bioxyne is positioned for continued growth in FY2026, attributable to further expansion of its business in Australia as well as entry into new high-growth opportunity markets including the UK, Germany and other EU countries.

<sup>1</sup> [Market Research Future](#)

<sup>2</sup> [The Business Research Company](#)



The Company expects to deliver guidance for FY2026 in August.

This announcement has been approved by the Board for lodgement with the ASX.

**About Bioxyne Limited:**

Bioxyne Limited is an Australian pharmaceutical company focused on the development and commercialization of innovative medicines and active pharmaceutical ingredients. Through its subsidiary, Breathe Life Sciences, Bioxyne is expanding into the production of psychedelic compounds for therapeutic use.

For further information, please contact:

Bioxyne Limited  
Investor Relations  
Email: [info@bioxyne.com](mailto:info@bioxyne.com)  
Phone: +61 2 9078 8180  
Website: [www.bioxyne.com](http://www.bioxyne.com)



For personal use only

## About Bioxyne Ltd.

**Bioxyne Limited (ASX:BXN)** is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

## About Breathe Life Sciences (BLS)

**Breathe Life Sciences (“BLS”)** is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, lifestyle products, functional mushrooms and nootropics, and prescription medicines in Australia.
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe.
- c) Contract / white label manufacture of consumer health products for brands in Japan, UK and Europe in company-owned facilities.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®
  - **United Kingdom:** [drwatsoncbd.com](http://drwatsoncbd.com)
  - **Japan:** [nolcbn.com](http://nolcbn.com)
  - **UK / EU:** [breathelifesciences.com](http://breathelifesciences.com)
- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

**Corporate:** [bioxyne.com](http://bioxyne.com)

**Australia:** [bls.com.au](http://bls.com.au)

**International:** [breathelifesciences.com](http://breathelifesciences.com)

